Pediatric Brain Cancer

Children deserve brain cancer treatments that are not only effective but also safe and thoughtfully engineered for their growing bodies. Our leading candidate, DNX-2401, is an oncolytic virus designed to selectively target and destroy tumor cells while leaving healthy tissue unharmed. In early trials, this therapy has shown a strong safety profile and early signs of clinical benefit—even in the face of some of the most difficult-to-treat pediatric brain cancers, like diffuse midline glioma.

We collaborate with top pediatric oncology centers—including the Clínica Universidad de Navarra, Princess Máxima Center for Pediatric Oncology (Utrecht, Netherlands) and the Pediatric Neuro-Oncology Consortium (PNOC)—to ensure that our treatments are grounded in science, guided by pediatric specialists, and developed with care.

• Selective Action: DNX-2401 replicates only in tumor cells.
• Immune Activation: It is intended to promote long-lasting protection by training the immune system.
• Early Promise: Durable responses have been seen in initial studies.
• Committed Partners: Clinical trials are underway at leading pediatric institutions.

We’re advancing smarter trial designs that reflect the unique needs of pediatric patients, including repeat-dosing strategies and higher-dose protocols designed to maximize therapeutic benefit. With strong institutional support and a robust supply of ready-to-use product, we’re accelerating the path from lab to bedside.
At CVBio, every day brings new data, deeper insight, and renewed commitment. Because when it comes to pediatric brain tumors, good enough is never good enough.

We’re working toward a future where more kids can grow up brain-cancer-free—and we’re getting closer every day.